A DIAGNOSIS AND
Familial hypercholesterolemia (FH) is a genetic disorder
characterized by high levels of “bad cholesterol” in the blood (low
density lipoprotein or LDL). Individuals with this disorder have a
higher risk of heart disease and stroke—the leading causes of death
(1) Source: World Health Organization.
Although FH is a common genetic disorder, diagnosis rates are
particularly low. In 2009, Sanofi and the biotechnology company
Regeneron joined forces to develop Praluent®, a human monoclonal
antibody that reduces LDL cholesterol levels for patients with
familial or non-familial hypercholesterolemia not controlled by
statins. Praluent® was approved in 2015 by the United States health
authority, the Food and Drug Administration (FDA), as well as the
European Commission and is now available in the United States,
Germany, Austria, and Scandinavian countries.
Familial hypercholesterolemia, a genetic disorder.
AN OVER-THE-COUNTER TREATMENT FOR CHRONIC PAIN
One in eight people in the United States suffers from back pain.
More than 42 million people in the United States suffer from
chronic back pain(1).
(1) Source: 2011 Gallop Study.
In 2014, true to its commitment to patient-driven innovation,
Sanofi’s Consumer Healthcare entity introduced Icy Hot®
SmartRelief™ Back Pain Therapy, an advanced, affordable,
noninvasive solution to quickly relieve pain. This medical device
available without prescription uses TENS (Transcutaneous Electrical
Nerve Stimulation) technology to send electrical impulses (of
patient-adjusted intensity) to the painful areas. It blocks pain
and stimulates endorphin release. This treatment option,
recommended by healthcare professionals across the United States,
is both reusable and rechargeable. Following the success of the
original product in the United States, Icy Hot® Smart Relief™ Knee
& Shoulder Pain Therapy was introduced in 2015 to help those
suffering from shoulder and knee pain.